European Companies Search Engine

EU funding (€10.3M): Psych-STRATA - A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness Hor4 Sept 2022 EU Research and Innovation programme "Horizon"

Overview

Text

Psych-STRATA - A Stratified Treatment Algorithm in Psychiatry: A program on stratified pharmacogenomics in severe mental illness

A key problem in Mental Health is that up to one third of patients suffering from major mental disorders develop resistance against drug therapy. However, patients showing early signs of treatment resistance (TR) do not receive adequate early intensive pharmacological treatment but instead they undergo a stepwise trial-and-error treatment approach. This situation originates from three major knowledge and translation gaps: i.) we lack effective methods to identify individuals at risk for TR early in the disease process, ii.) we lack effective, personalized treatment strategies grounded in insights into the biological basis of TR, and iii.) we lack efficient processes to translate scientific insights about TR into clinical practice, primary care and treatment guidelines. It is the central goal of PSYCH-STRATA to bridge these gaps and pave the way for a shift towards a treatment decision-making process tailored for the individual at risk for TR. To that end, we aim to establish evidence-based criteria to make decisions of early intense treatment in individuals at risk for TR across the major psychiatric disorders of schizophrenia, bipolar disorder and major depression. PSYCH-STRATA will i.) dissect the biological basis of TR and establish criteria to enable early detection of individuals at risk for TR based on the integrated analysis of an unprecedented collection of genetic, biological, digital mental health, and clinical data. ii.) Moreover, we will determine effective treatment strategies of individuals at risk for TR early in the treatment process, based on pan-European clinical trials in SCZ, BD and MDD. These efforts will enable the establishment of novel multimodal machine learning models to predict TR risk and treatment response. Lastly, iii.) we will enable the translation of these findings into clinical practice by prototyping the integration of personalized treatment decision support and patient-oriented decision-making mental health boards.


Funded Companies:

Company name Funding amount
Cardiff University ?
Alma Mater Studiorum - Universita Di Bologna €249,308
Associazione Oasi Maria SS. Onlus €175,000
Charite - Universitaetsmedizin Berlin €301,014
European Research Services GmbH €142,288
Fraunhofer Gesellschaft ZUR Forderung DER Angewandten Forschung e. V. €509,695
Fundacio Centre de Regulacio Genomica €126,520
Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer €132,500
Fundacion para La Investigacion Biomedica del Hospital Gregorio Maranon €30,010
Global Alliance OF Mental Illness Advocacy Networks Europe Aisbl €167,020
Goeteborgs Universitet €181,115
Hospital Clinic de Barcelona €0.00
Institut du Cerveau et de la Moelle Epiniere €419,210
Kairos GmbH €203,125
Karlsruher Institut Fuer Technologie €272,780
Katholieke Universiteit Leuven €155,405
Klinikum DER Ludwig-Maximilians-Universitat Munchen €0.00
Ludwig-Maximilians-Universitaet Muenchen €368,011
MAX-Planck-Gesellschaft ZUR Forderung DER Wissenschaften e. V. €87,250
Novamechanics Ltd. €0.00
Novamechanics Monoprosopi ΙΚΕ €450,000
Oslo Universitetssykehus HF €653,125
Region Hovedstaden €65,424
Universita Degli Studi Di Brescia €144,702
Universita Degli Studi Di Cagliari €337,843
Universitaet Muenster €3,753,832
Universitair Medisch Centrum Utrecht €1,351,265
Universitetet I Oslo €0.00

Source: https://cordis.europa.eu/project/id/101057454

The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Cardiff University, Cardiff.